Bristol Myers Squibb Is Paying $350M to Expand Its Reach in Radiopharmaceuticals to Prostate Cancer

Bristol Myers Squibb’s efforts to diversify its cancer portfolio beyond immunotherapies brought radiopharmaceuticals to its pipeline. Now it’s expanding its radiopharmaceuticals scope to ...